Literature DB >> 1614046

Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.

P A Gabow1, A M Johnson, W D Kaehny, W J Kimberling, D C Lezotte, I T Duley, R H Jones.   

Abstract

Autosomal-dominant polycystic kidney disease results in renal failure at a varying age from childhood to old age. We postulated that factors other than the culprit gene alone contribute to the course of progression of the renal failure. We studied 580 subjects with autosomal-dominant polycystic kidney disease and 194 unaffected family members. We calculated survival curves to end-stage renal failure or death and developed a linear model for testing the effects of single or multiple variables on the progression of renal failure as estimated from the reciprocal of serum creatinine. Fifty-two subjects died and 94 reached end-stage renal failure during the period of observation, yielding functional survivals of 71% at age 50 years, 53% at 58 years and 23% at 70 years. The following variables were independently associated with worse mean renal function at a given age (P value less than 0.01): the PKD1 gene, younger age at diagnosis, male gender, hypertension, increased left ventricular mass, hepatic cysts in women, three or more pregnancies, gross hematuria, urinary tract infections in men and renal size expressed as renal volume. The following were not associated significantly with the course of renal function: gender of affected parent, mitral valve prolapse, intracranial aneurysms, any pregnancy, hepatic cysts in men and urinary tract infections in women. The identification of unalterable maleficent factors such as the PKD1 gene and male gender permit more informed counseling while the identification of alterable factors such as hypertension, number of pregnancies and recurrent urinary tract infections provides the clinician with the opportunity to modify these factors and improve the management of patients with autosomal-dominant polycystic kidney disease.

Entities:  

Mesh:

Year:  1992        PMID: 1614046     DOI: 10.1038/ki.1992.195

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  122 in total

1.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

2.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

3.  A spectrum of mutations in the second gene for autosomal dominant polycystic kidney disease (PKD2).

Authors:  B Veldhuisen; J J Saris; S de Haij; T Hayashi; D M Reynolds; T Mochizuki; R Elles; R Fossdal; N Bogdanova; M A van Dijk; E Coto; D Ravine; S Nørby; C Verellen-Dumoulin; M H Breuning; S Somlo; D J Peters
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

4.  Automatic 3D Segmentation of the Kidney in MR Images Using Wavelet Feature Extraction and Probability Shape Model.

Authors:  Hamed Akbari; Baowei Fei
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2013-02-23

5.  Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Authors:  Kristen L Nowak; Berenice Gitomer; Heather Farmer-Bailey; Wei Wang; Mikaela Malaczewski; Jelena Klawitter; Zhiying You; Diana George; Nayana Patel; Anna Jovanovich; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2019-02-23       Impact factor: 8.860

6.  Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

Authors:  Piero Ruggenenti; Giorgio Gentile; Norberto Perico; Annalisa Perna; Luca Barcella; Matias Trillini; Monica Cortinovis; Claudia Patricia Ferrer Siles; Jorge Arturo Reyes Loaeza; Maria Carolina Aparicio; Giorgio Fasolini; Flavio Gaspari; Davide Martinetti; Fabiola Carrara; Nadia Rubis; Silvia Prandini; Anna Caroli; Kanishka Sharma; Luca Antiga; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-22       Impact factor: 8.237

7.  Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Pamela Mettler; Kim Mc Fann; Oleksandra Tkachenko; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Nephrol       Date:  2012-10-04       Impact factor: 3.754

8.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

9.  Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.

Authors:  C J Ward; H Turley; A C Ong; M Comley; S Biddolph; R Chetty; P J Ratcliffe; K Gattner; P C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

10.  A young patient with a family history of hypertension.

Authors:  Aldo J Peixoto
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.